FRANK ABENANTE: Open Payments
NPI 1730273418 · MANAHAWKIN, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,294 in 104 payments from 12 companies in 2025. Trend: 2023 $25,059 · 2024 $20,833 · 2025 $6,294
Speaker / faculty: $4,500Food & beverage: $1,772Education: $23
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $4,770 |
| Teva Pharmaceuticals USA, Inc. | 40 | $605 |
| Otsuka America Pharmaceutical, Inc. | 14 | $252 |
| Axsome Therapeutics, Inc. | 8 | $166 |
| Neurocrine BioSciences, Inc. | 7 | $122 |
| Bausch Health US, LLC | 5 | $81 |
| Lundbeck LLC | 4 | $78 |
| Alkermes, Inc. | 4 | $66 |
| E.R. Squibb & Sons, L.L.C. | 4 | $63 |
| IDORSIA PHARMACEUTICALS US INC | 2 | $40 |
Products named: VRAYLAR, AUSTEDO XR, REXULTI, Auvelity, INGREZZA, APLENZIN, ARISTADA, COBENFY.
Industry payments across NJ — which companies pay providers there.
